Medicamen Biotech Limited (MBL) is pleased to announce that it has entered into an understanding with a prominent South African business conglomerate for registering and marketing its products in the region. South Africa represents a $4 billion pharmaceutical market and is categorized as a regulated market.
The recent EU approval of MBL's plant has opened new avenues to explore such opportunities, aligning with the company's strategic vision of global expansion. The management is confident in leveraging this milestone to further strengthen its presence in regulated markets and drive future growth.
Shares of MEDICAMEN BIOTECH LTD. was last trading in BSE at Rs. 481.15 as compared to the previous close of Rs. 487.45. The total number of shares traded during the day was 1906 in over 335 trades.
The stock hit an intraday high of Rs. 508.00 and intraday low of 478.45. The net turnover during the day was Rs. 935020.00. |
